Dexcom (DXCM) EVP sells 1,700 shares, still holds 111,204

Rhea-AI Filing Summary

Dexcom Inc.’s EVP and Chief Legal Officer Michael Jon Brown sold 1,700 shares of common stock in an open-market transaction. The shares were sold at $63.04 each under a pre-arranged Rule 10b5-1 trading plan adopted on November 26, 2025.

Following this sale, Brown directly owns 111,204 Dexcom shares77,603 unvested RSUs, with grants made on March 8, 2026, March 8, 2025, and March 8, 2024 that are scheduled to vest through March 8, 2029.

Insider Trade Summary 10b5-1

Net Seller: 1,700 shares ($107,168)

Net Sell 1 txn

Insider Brown Michael Jon

Role EVP, Chief Legal Officer

Sold 1,700 shs ($107K)

Type	Security	Shares	Price	Value
Sale	Common Stock	1,700	$63.04	$107K

Holdings After Transaction: Common Stock — 111,204 shares (Direct)

Footnotes (1)

1. On November 26, 2025, Mr. Brown adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Brown. The shares set forth above were sold pursuant to the 10b5- 1 Plan. Included in this number are 77,603 unvested RSUs, 39,019 of which were granted on March 8, 2026 and shall vest through March 8, 2029, 19,948 of which were granted on March 8, 2025 and shall vest through March 8, 2028, 11,399 of which were granted on March 8, 2025 and shall vest through March 8, 2027, and 7,237 of which were granted on March 8, 2024 and shall vest through March 8, 2027.

Key Figures

Shares sold: 1,700 shares Sale price: $63.04 per share Shares owned after sale: 111,204 shares +5 more

8 metrics

Shares sold 1,700 shares Open-market sale on April 15, 2026

Sale price $63.04 per share Price received in the April 15, 2026 sale

Shares owned after sale 111,204 shares Direct Dexcom holdings following the reported transaction

Unvested RSUs included 77,603 RSUs Portion of Brown’s 111,204-share holding that is unvested RSUs

2026 RSU grant 39,019 RSUs Granted March 8, 2026, vesting through March 8, 2029

2025 RSU grants 19,948 and 11,399 RSUs Granted March 8, 2025, vesting through March 8, 2028 and March 8, 2027

2024 RSU grant 7,237 RSUs Granted March 8, 2024, vesting through March 8, 2027

Trading plan adoption date November 26, 2025 Date Brown adopted his Rule 10b5-1 Plan

Key Terms

Rule 10b5-1 Plan, unvested RSUs, open-market sale

3 terms

Rule 10b5-1 Plan regulatory

"This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Brown."

A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.

unvested RSUs financial

"Included in this number are 77,603 unvested RSUs, 39,019 of which were granted on March 8, 2026"

open-market sale financial

"transaction_action: "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Form 4 Insider Transactions: What Each Field Means →

04/16/2026 - 07:27 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Brown Michael Jon

(Last) (First) (Middle)

6340 SEQUENCE DRIVE

(Street)

SAN DIEGO CALIFORNIA 92121

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
DEXCOM INC [ DXCM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, Chief Legal Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	04/15/2026		S		1,700(1)	D	$63.04	111,204(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. On November 26, 2025, Mr. Brown adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Brown. The shares set forth above were sold pursuant to the 10b5- 1 Plan.

2. Included in this number are 77,603 unvested RSUs, 39,019 of which were granted on March 8, 2026 and shall vest through March 8, 2029, 19,948 of which were granted on March 8, 2025 and shall vest through March 8, 2028, 11,399 of which were granted on March 8, 2025 and shall vest through March 8, 2027, and 7,237 of which were granted on March 8, 2024 and shall vest through March 8, 2027.

Remarks:

	/s/ Jereme M. Sylvain, as Attorney-in-Fact for Michael Jon Brown	04/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Dexcom (DXCM) executive Michael Jon Brown report in this Form 4?

Michael Jon Brown, EVP and Chief Legal Officer of Dexcom, reported selling 1,700 shares of common stock at $63.04 per share. The transaction was an open-market sale executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 26, 2025.

How many Dexcom (DXCM) shares does Michael Jon Brown hold after the reported sale?

After selling 1,700 shares, Michael Jon Brown directly holds 111,204 Dexcom common shares. This total includes both vested and unvested equity, specifically 77,603 unvested RSUs with scheduled vesting dates extending through March 8, 2029.

What is the significance of the Rule 10b5-1 plan mentioned in Dexcom (DXCM) insider filing?

The filing notes Brown adopted a Rule 10b5-1 Plan on November 26, 2025, allowing orderly, pre-scheduled share sales. The 1,700 shares in this transaction were sold pursuant to that plan, indicating the sale was planned in advance rather than opportunistic market timing.

What unvested RSUs are included in Michael Jon Brown’s Dexcom (DXCM) holdings?

Brown’s 111,204-share holding includes 77,603 unvested RSUs. Of these, 39,019 were granted March 8, 2026, 19,948 and 11,399 were granted March 8, 2025, and 7,237 were granted March 8, 2024, with vesting running through March 8, 2029.

Was the Dexcom (DXCM) insider transaction a market purchase or sale of shares?

The Form 4 shows an open-market sale of Dexcom common stock. Brown sold 1,700 shares at $63.04 per share, coded as an “S” transaction, which denotes a sale in an open-market or private transaction under SEC reporting rules.